---
title: "Buprenorphine Presentation"
author: "Matthew Hoctor, PharmD"
date: "`r format(Sys.time(), '%d %B, %Y')`"

format:
  revealjs:
    logo: presentation/ohsu-psu.jpg
  beamer:
    logo: presentation/ohsu-psu.jpg
  
toc: true
toc-depth: 3
# toc-location: left
# toc-title: Contents
  
code-fold: true
code-overflow: wrap
# code-tools: true
# code-link: true

editor: source
---

```{r}
#| label: setup
#| output: false
1 + 1
```

# Background

## OUD Epidemiology

## OUD Treatment

## Buprenorphine Law

Drug Addiction Treatment Act (DARA), 2002

-   Allowed X-waivered physicians to prescribe for OUD

Buprenorphine Approved, 2002

-   Schedule III: no DEA manufacturing quota
-   Approved for use outside of specialized treatment centers

Comprehensive Addiction and Recovery Act (CARA), 2016

-   Extended X-waiver to NPs and PAs; required 24h of training
-   Set budget specifically to address OUD epidemic

Consolidated Appropriations Act (MAT), 2023

-   Removed X-waiver requirement

## Motivation

# Analysis

# Results

# Conclusion

## Challenges

# References
